All In Biotech

Free tool

FAERS Monitor: Fml

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 016851 or its brand name (Fml, Fluorometholone). Reports on generic versions are filed under their own applications.

Reports

3,120

Serious

1,612

52% of reports

Hospitalization

790

Death reported

316

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • treatment failure371
  • drug ineffective232
  • eye pain224
  • off label use217
  • fatigue212
  • diarrhoea180
  • headache177
  • dyspnoea173
  • arthralgia167
  • eye irritation158
  • condition aggravated153
  • dizziness146
  • pruritus146
  • nausea145
  • anxiety142

Reports by year received

View as table
YearReports
200411
20056
200614
200710
200813
200921
201043
201137
201263
201352
201462
201585
2016176
2017141
2018147
2019168
2020453
2021215
2022234
2023247
2024297
2025353
2026272

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,051,039 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
treatment failureSignal37130.327.610,484
eye painSignal22426.923.75,546
eye irritationSignal15818.615.92,606
condition aggravatedSignal1533.42.9260
anxietySignal1423.42.9237
arthralgiaSignal1672.72.3182
pruritusSignal1462.62.2140
dyspnoeaSignal1732.11.896
dizziness1462.01.771
headache1771.91.677
diarrhoea1801.91.676
fatigue2121.81.683
off label use2171.71.560
nausea1451.21.16
drug ineffective2321.21.07

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.